Vitamin d deficiency in mycosis fungoides and sézary syndrome patients is similar to other cancer patients

Rakhshandra Talpur, Katherine M. Cox, Mimi Hu, Elizabeth R. Geddes, Mary K. Parker, Betty Y. Yang, Patrick A. Armstrong, Ping Liu, Madeleine Duvic

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Vitamin D deficiency (< 30 ng/mL serum vitamin D [25(OH)D3]) found in 239 of 311 (76.9%) cutaneous T-cell lymphoma (CTCL) patients was comparable to 238 controls including 127 of 169 (75.2%) of cancer controls and 46 of 69 (66.7%) of healthy controls (P=.05, .07). Supplementation with D2 or D3 corrected only about a third of patients' levels and did not affect response to therapy.Background: The purpose of this study was to determine the prevalence of vitamin D deficiency in CTCL patients and whether supplementation corrects vitamin D deficiency or treatment outcome .Patients and Methods: Three hundred eleven CTCL patients including 27/311 (8.7%) with Sézary syndrome (SS), 169 cancer controls, and 69 normal controls from the M.D. Anderson clinics had 25(OH)D3 levels determined and categorized as deficient (< 20 ng/mL), insufficient (20-29 ng/mL), or sufficient (≥ 30 ng/mL). Clinical response was determined according to a change in percent body surface area involvement . Results: Low 25(OH)D3 (< 30 ng/mL) levels were present in 76.9% of mycosis fungoides/SS patients, 75.2% of cancer controls, and 66.7% of healthy controls (P = .05, .07) and in 30% to 39% of historical normal controls. Correction of deficiency was successful in 35% or 55 of 156 patients who were given dealer's choice of either vitamin D2 at 50,000 IU orally (p.o.) biweekly or D3 1000 IU p.o. daily. Correction of vitamin D levels was noted in 27 of 100 (27%) patients given D3 and 28 of 56 (50%) given D2. Responses to standard CTCL therapy was similar among patients with corrected and persistently low levels (P = .51). Conclusion: To our knowledge, this is the first study of vitamin D status in CTCL patients. Vitamin D deficiency was present in CTCL and other cancer patients compared with normal and historical controls. Correction of vitamin D deficiency and type of vitamin D supplementation used did not affect the overall clinical disease response .

Original languageEnglish (US)
Pages (from-to)518-524
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number6
StatePublished - 2014
Externally publishedYes


  • 25(OH)D3
  • 25-OH vitamin D2
  • Cutaneous T-cell lymphoma (CTCL)
  • T-cell lymphoma
  • Vitamin D

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Vitamin d deficiency in mycosis fungoides and sézary syndrome patients is similar to other cancer patients'. Together they form a unique fingerprint.

Cite this